Technical Analysis for GH - Guardant Health, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 17.35 | 1.11% | 0.19 |
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 1.11% | |
| Gapped Down | Weakness | 1.11% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -4.14% | |
| MACD Bullish Signal Line Cross | Bullish | -4.14% | |
| NR7 | Range Contraction | -4.14% | |
| Inside Day | Range Contraction | -4.14% | |
| Wide Bands | Range Expansion | -4.14% | |
| Gapped Up | Strength | -4.14% | |
| 20 DMA Resistance | Bearish | 0.06% |
| Alert | Time |
|---|---|
| Possible NR7 | about 12 hours ago |
| Up 2% | about 16 hours ago |
| Up 1% | about 16 hours ago |
| 10 DMA Support | about 16 hours ago |
| Fell Below Previous Day's Low | about 16 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/09/2024
Guardant Health, Inc. Description
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Biopharmaceutical Cancer Disease Clinical Development Oncology Telehealth Telemedicine Lab Testing Precision Medicine Blood Test Biopsy Healthcare Costs
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 41.06 |
| 52 Week Low | 15.81 |
| Average Volume | 2,109,609 |
| 200-Day Moving Average | 26.38 |
| 50-Day Moving Average | 18.77 |
| 20-Day Moving Average | 18.02 |
| 10-Day Moving Average | 16.99 |
| Average True Range | 1.12 |
| RSI (14) | 46.24 |
| ADX | 15.92 |
| +DI | 21.03 |
| -DI | 22.86 |
| Chandelier Exit (Long, 3 ATRs) | 19.21 |
| Chandelier Exit (Short, 3 ATRs) | 19.17 |
| Upper Bollinger Bands | 20.61 |
| Lower Bollinger Band | 15.42 |
| Percent B (%b) | 0.37 |
| BandWidth | 28.79 |
| MACD Line | -0.50 |
| MACD Signal Line | -0.55 |
| MACD Histogram | 0.0489 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.48 | ||||
| Resistance 3 (R3) | 18.41 | 17.96 | 18.29 | ||
| Resistance 2 (R2) | 17.96 | 17.68 | 18.00 | 18.22 | |
| Resistance 1 (R1) | 17.66 | 17.50 | 17.81 | 17.73 | 18.16 |
| Pivot Point | 17.21 | 17.21 | 17.29 | 17.25 | 17.21 |
| Support 1 (S1) | 16.91 | 16.93 | 17.06 | 16.98 | 16.54 |
| Support 2 (S2) | 16.46 | 16.75 | 16.50 | 16.48 | |
| Support 3 (S3) | 16.16 | 16.46 | 16.41 | ||
| Support 4 (S4) | 16.23 |
